Therapeutic banner
Therapeutic banner

Transthyretin (ATTR) Amyloidosis

View the latest scientific data presented at congress events in the past 2 years and discover peer-reviewed publications related to ATTR Amyloidosis.
The information on this page pertains to select congress and publication resources. It is not intended to serve as a comprehensive list of all congress and publications resources.

Publications

Transthyretin Amyloidosis (ATTR)

Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial

Amyloid

Author(s)

David Adams, Ivailo Tournev, Mark Taylor, et al

Transthyretin Amyloidosis (ATTR)

Patisiran treatment in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy after liver transplantation

American Journal of Transplantation

Author(s)

Hartmut Schmidt, Jonas Wixner, Violaine Planté-Bordeneuve, et al

Transthyretin Amyloidosis (ATTR)

Presence of the V122I Variant of Hereditary Transthyretin-Mediated Amyloidosis Among Self-Reported White Individuals in a Sponsored Genetic Testing Program

Circulation: Genomic and Precision Medicine

Author(s)

Barry Trachtenberg, Sachin Shah, Robert Nussbaum, et al

Transthyretin Amyloidosis (ATTR)

Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study

The Lancet Neurology

Author(s)

David Adams, Michael Polydefkis, Alejandra González-Duarte, et al

Transthyretin Amyloidosis (ATTR)

Transthyretin-stabilising mutation T119M is not associated with protection against vascular disease or death in the UK Biobank

Amyloid

Author(s)

Margaret M Parker, Simina Ticau, James Butler, et al

Transthyretin Amyloidosis (ATTR)

Investigating the pharmacodynamic durability of GalNAc-siRNA conjugates

Nucleic Acids Research

Author(s)

Christopher Brown, Swati Gupta, June Qin, et al